

MODALITÀ DI ISCRIZIONE

È possibile effettuare l'iscrizione sul sito
www.formatsas.com

La segreteria invierà una **comunicazione di conferma della prenotazione**, con indicazioni per completare la procedura di iscrizione e inserire i documenti relativi al pagamento o all'impegno di spesa dell'Ente di appartenenza.

Dal momento della prenotazione vi sono **3 giorni** di tempo per effettuare il pagamento tramite bonifico bancario, indicando come causale: nome, cognome e codice evento, **intestato a:**

FORMAT sas - Via del Brennero 136 - Trento
Cassa di Risparmio di Bolzano
COD. IBAN: IT04F 06045 01802 00000 0091700

Le prenotazioni e le iscrizioni verranno accettate in ordine cronologico. **Dopo 3 giorni, se la procedura di iscrizione non verrà completata, il posto riservato potrà essere reso disponibile.**

L'iscrizione si intende completata al ricevimento di una email da parte della segreteria per la **conferma dell'iscrizione.**

Tutte le comunicazioni relative all'evento verranno trasmesse solamente tramite email, pertanto Format non si assume la responsabilità nel caso in cui le comunicazioni via email siano ignorate. Il corsista si impegna ad indicare l'indirizzo email valido, a visionarlo con frequenza e a rispondere alle comunicazioni pervenute.

Per richieste di assistenza è possibile scrivere all'indirizzo iscrizioni@formatsas.com oppure contattare la segreteria: 0533-713275 o 0461-825907.

DISDETTE E RIMBORSI

In caso di disdetta entro il termine delle iscrizioni, verrà restituito il 50% della quota versata.

In tutti gli altri casi non verrà effettuato nessun rimborso.

FORMAT si riserva di non attivare il corso qualora non sia raggiunto il numero minimo di partecipanti previsto. In questo caso verranno concordate con gli iscritti le modalità di riutilizzo della quota o di rimborso. Eventuali spese viaggio o pernottamento già sostenute dal partecipante o dall'Azienda di appartenenza non potranno essere rimborsate.

●● Event code

TYR0119BZZ009

●● Event language

inglese

●● Event schedule

20TH september: 10.45/12.40 – 13.40/17.20

21ST september: 09.00/12.20 – 13.30/15.30

●● Deadline for registration

16/09/2019

●● Participation fee

€ 480,00* (IVA esente art. 10 DPR 633/72
(*partecipazione all'evento, lunch e coffe break
previsti nel programma)

●● Unconditional contribution

being defined

ECM Provider



via del Brennero 136 - Trento

Tel. 0533 713 275

info@formatsas.com - www.formatsas.com

Iscrizione al Registro delle Imprese di Ferrara, C.F. e P.I. 01569060385 – REA FE 178788



Azienda con sistema di qualità
certificato ISO 9001:2015



Provider ECM Standard
Min. Salute 514

E.C.M.
Educazione Continua
in Medicina

TYROLEAN MEETING

INTERNATIONAL CONGRESS ON ADVANCES
IN MEDICAL THERAPY IN CARDIOLOGY

20th - 21st september 2019



Sheraton Hotel – Bolzano
Via Bruno Buozzi 35

SCIENTIFIC DIRECTOR

R. Cemin (Bolzano – Italy)

ADVISORY BOARD

R. Cemin (Bolzano – Italy)

R. De Caterina (Pisa – Italy)

R. Oberhollenzer (Bolzano – Italy),

K. Parhofer (Munich – Germany)

F. Ribichini (Verona – Italy)





●● Under the patronage of

being defined

●● Assumption

Acute coronary syndrome, atrial fibrillation, dyslipidaemias and advanced heart failure are medical problems increasingly absorbing a significant amount of resources all over the world and their treatment is rapidly evolving.

Aside to the intensified resort to mechanic revascularisations procedures (i.e. percutaneous coronary intervention), and to electrophysiological ablation procedures, many antiplatelet, anticoagulant and lipid lowering drugs have been developed in the last years. The new agents offer great opportunities in patients' treatment, but their use is still conflicting in the different settings. Furthermore, doctors encounter daily clinical situations, where the use of these drugs are not clearly codified and remains uncertain.

Recently an increased attention to out of hospital treatment of chronic heart failure has been promoted in order to reduce rehospitalisations. Guidelines have been repeatedly updated and should be continuously explained in detail in order to facilitate its application in daily clinical practice.

Antiplatelet, anticoagulant, lipid lowering and heart failure therapies play a central role in modern cardiology and proper knowledge of their indication should be part of every physician's expertise.

●● Purpose

Purpose of the present meeting is to afford the modern approach to heart failure and newly developed antithrombotic (antiplatelet and anticoagulant) and lipid lowering agents, the indications to their use in various clinical settings and the best therapeutic strategies, through talks held by some of the most expert physician in the field around Europe.

●● Participants

Medici Chirurghi (tutte le discipline)
100 posti disponibili

●● ECM credits

10

FRIDAY, 20TH SEPTEMBER

10.45 **INTRODUCTION**
R. Oberhollenzer (Bolzano – Italy)

HOT-TOPICS IN THE ERA OF DIRECT ORAL ANTICOAGULANT AGENTS

Chairmen: R. De Caterina (Pisa – Italy)
R. Cemin (Bolzano – Italy)

10.50 How to check and improve adherence of direct oral anticoagulants

T. Potpara (Belgrade – Serbia)

11.10 Direct oral anticoagulants in advanced and end stage renal failure

P. Sinnaeve (Leuven – Belgium)

11.30 Cardioversion in direct oral anticoagulants' era. Are there still some black holes to be addressed?

H. Bonnemeier (Kiel – Germany)

11.50 Direct oral anticoagulants after TAVI procedures

F. Ribichini (Verona – Italy)

12.10 Discussion

12.40 **Lunch**

PRACTICAL ASPECTS IN THE DIRECT ORAL ANTICOAGULANT THERAPY

Chairmen: R. Cemin (Bolzano – Italy),
H. Bonnemeier (Kiel – Germany)

13.40 Triple or Dual antithrombotic therapy soon after stenting in patients with AF

R. De Caterina (Pisa – Italy)

14.00 The unsolved problem of ESUS (Embolic stroke of undetermined source)

M. Antz (Braunschweig – Germany)

14.20 AF detected with implantable devices: when is it indicated to start long-term anticoagulation?

R. Cappato (Milan – Italy)

14.40 Discussion

15.10 **Coffee break**

HEART FAILURE

Chairmen: A. Maggioni (Florence – Italy)
R. De Caterina (Pisa – Italy)

15.30 The innovation in heart failure

A. Maggioni (Florence – Italy)

15.50 Amyloidosis: the emerging problem

A. Wechalekar (London – United Kingdom)

16.10 Intermittent inotropes for ambulatory advanced heart failure

G. Malfatti (Milan – Italy)

16.30 When all else fails - initial/ongoing management in cardiogenic shock

S. Price (London – United Kingdom)

16.50 Discussion

SATURDAY, 21ST SEPTEMBER

LIPID LOWERING THERAPY

Chairmen: C. Bilato (Arzignano – Italy)
C. Fresco (Udine – Italy)

09.00 PCSK9-inhibitor outcome studies

K. Parhofer (Munich – Germany)

09.20 Do we even need LDL-cholesterol

L. Masana (Tarragona – Spain)

09.40 New guidelines - new drugs

A. Zambon (Padua – Italy)

10.00 Discussion

10.30 **Coffee break**

ANTIPLATELET THERAPY AND CARDIOVASCULAR DISEASES

Chairmen: G. Pesarini (Verona – Italy)
P. Marschang (Bolzano – Italy)

10.50 Aspirin in primary cardiovascular prevention: a fall from grace?

C. Bilato (Arzignano – Italy)

11.10 Patients with stable peripheral and carotid artery disease. Why to choose dual antiplatelet therapy

S. James (Uppsala – Sweden)

11.30 Patients with stable peripheral or carotid artery disease. Why to choose dual pathway therapy

M. Alings (Breda – The Netherlands)

11.50 Discussion

12.20 **Lunch**

ANTIPLATELET THERAPY AND ACUTE CORONARY SYNDROME

Chairmen: F. Ribichini (Verona – Italy)
R. Oberhollenzer (Bolzano – Italy)

13.30 Early initiation of antiplatelets in ACS: facts and fiction about pretreatment

R. Byrne (Munich – Germany)

13.50 Will Cangrelor change our clinical practice?

P. Widimsky (Prague – Czech Republic)

14.10 Balancing benefit and risk in combining anticoagulants and antiplatelets in ACS patients

K. Huber (Wien – Austria)

14.30 Optimising antiplatelet strategies in ACS patients: where are we now?

Halvorsen S. (Oslo – Norway)

14.50 Discussion

15.20 **CLOSING REMARKS**

R. Cemin (Bolzano – Italy)

